

# In the News

## Update to Infliximab Product Coverage for Medical Mutual Plans

Effective June 1, 2019, certain infliximab products will be considered non-preferred medications. Members new to the therapy will require a trial of two preferred infliximab products before a non-preferred product can be prescribed.

Infliximab is a tumor necrosis factor inhibitor (TNFi) agent used to treat many types of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

The preferred infliximab products for Medical Mutual commercial and ACA plans are noted on the left side of the following chart. The non-preferred products are shown on the right.

Preferred Products*	Non-preferred Products
<ul style="list-style-type: none"><li>• Remicade (infliximab)</li><li>• Renflexis (infliximab-abda)</li></ul>	<ul style="list-style-type: none"><li>• Inflectra (infliximab-dyyb)</li><li>• Ixifi (infliximab-qbtx)</li></ul>

\*Preferred products are subject to any benefit limitation set forth in a member's benefit certificate.

For more information, please visit [Medmutual.com/provider](https://www.medmutual.com/provider), [Tools and Resources](#), [Care Management](#), [Corporate Medical Policies](#).